Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase 1/2 Inhibitor, in Adults with Alopecia Areata: Results from the THRIVE-AA2 Phase 3, Randomized, Double-Blind, Controlled Trial

The THRIVE-AA2 Phase 3 trial assessed the efficacy and safety of deuruxolitinib, a Janus kinase 1/2 inhibitor, in 517 adults with severe chronic alopecia areata. Participants received either 12 mg or 8 mg of deuruxolitinib twice daily, or a placebo, for 24 weeks. Results indicated that 38.3% of patients on the 12 mg dose and 33.0% on the 8 mg dose achieved significant hair regrowth, compared to 0.8% in the placebo group. The treatment was well tolerated, with mostly mild or moderate adverse events. The study supports deuruxolitinib as a promising treatment for alopecia areata, though further investigation into long-term efficacy and safety is needed.